SKIN Stock Forecast & Price Target

SkinHealth Systems is supported by a resilient consumables engine, with recurring revenue making up about 75% of sales and 3Q consumables returning to growth at $50.4 million, up 1.2% year over year, led by the Americas and SkinStylus expansion. Although Delivery Systems remained pressured, the active installed base grew to 36,516 systems and management’s rental program, improved sales-force execution, and corporate-account expansion should reduce financing friction and eventually revive placements. Profitability has also outperformed, with 3Q revenue of $69.2 million above Street expectations, adjusted gross margin of 71.8%, and adjusted EBITDA margin of 19.3%, while new launches and a 2027 and 2028 product roadmap add further growth catalysts.

SkinHealth Systems is facing a weak fundamental setup as Delivery Systems sales fell 9.6% y/y to $18.8mm, systems placed declined 8.8% y/y, and management said utilization remains below expectations despite a new U.S. rental program that was not yet a meaningful 3Q contributor. The bearish view is reinforced by deteriorating provider relationships, challenged brand equity, and uneven regional performance, with EMEA down about 12% and 3Q26 revenue guidance of $65-70MM and adj. EBITDA of $5-7MM both below Street expectations. Although cash of about $206M exceeds its ~$91M market cap, visibility into a durable recovery is limited by lowered FY26 revenue guidance, pressured consumables utilization, and the $250MM November 2028 convert maturity.